Clinical utility of chromogranin A in SDHx‐related paragangliomas
暂无分享,去创建一个
[1] J. Carrasquillo,et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. , 2012, Journal of the National Cancer Institute.
[2] P. Dahia,et al. An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary Syndromes , 2012, Hormone and Metabolic Research.
[3] L. Hofbauer,et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. , 2011, Clinical chemistry.
[4] S. Bornstein,et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. , 2010, Endocrine-related cancer.
[5] I. Modlin,et al. Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease , 2010, Annals of Surgical Oncology.
[6] A. Vinik,et al. Biochemical Testing for Neuroendocrine Tumors , 2009, Pancreas.
[7] A. Vénisse,et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. , 2009, The Journal of clinical endocrinology and metabolism.
[8] M. Merino,et al. Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. , 2008, The Journal of clinical endocrinology and metabolism.
[9] C. Schmid,et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[10] L. Ceriani,et al. Diagnostic value of serum chromogranin-A combined with MIBG scintigraphy inpatients with adrenal incidentalomas. , 2008, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[11] W. Young,et al. Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. , 2008, The Journal of clinical endocrinology and metabolism.
[12] K. Pacak,et al. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. , 2007, The Journal of clinical endocrinology and metabolism.
[13] L. Ceriani,et al. Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan. , 2006, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[14] M. Boniardi,et al. The role of chromogranin A in the management of patients with phaeochromocytoma , 2006, Clinical endocrinology.
[15] Tom Greene,et al. Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.
[16] S. Richard,et al. Genetic testing in pheochromocytoma or functional paraganglioma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Goldstein,et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. , 2005, The Journal of clinical endocrinology and metabolism.
[18] M. Walther,et al. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. , 2005, Clinical chemistry.
[19] C. Eng,et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. , 2004, JAMA.
[20] K. Pacak,et al. Biochemical diagnosis of pheochromocytoma. , 2004, Frontiers of hormone research.
[21] S. Bloom,et al. Neuroendocrine tumours. , 2014, Endocrine-related cancer.
[22] D. Marsh,et al. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas , 2003, Oncogene.
[23] M. Walther,et al. Biochemical diagnosis of pheochromocytoma: which test is best? , 2002, JAMA.
[24] W. Young,et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. , 2001, The Journal of clinical endocrinology and metabolism.
[25] Y. Loh,et al. Chromogranin A, an “On/Off” Switch Controlling Dense-Core Secretory Granule Biogenesis , 2001, Cell.
[26] E. Baudin,et al. Chromogranin A and the α -subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma , 2001, British Journal of Cancer.
[27] M. Ferdeghini,et al. RELATIONSHIP BETWEEN RENAL FUNCTION AND BLOOD LEVEL OF CHROMOGRANIN A , 2001, Renal failure.
[28] T. Benraad,et al. Highly sensitive and specific HPLC with fluorometric detection for determination of plasma epinephrine and norepinephrine applied to kinetic studies in humans. , 1995, Clinical chemistry.
[29] D. Goldstein,et al. Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. , 1993, Clinical chemistry.
[30] D. O'Connor,et al. Chromogranin A Storage and Secretion: Sensitivity and Specificity for the Diagnosis of Pheochromocytoma , 1991, Medicine.
[31] D. O'Connor,et al. Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. , 1990, The American journal of medicine.
[32] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[33] D. Murphy,et al. Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. , 1986, Clinical chemistry.
[34] D. O'Connor,et al. Secretion of chromogranin A by peptide-producing endocrine neoplasms. , 1986, The New England journal of medicine.